USPTO serial 79362452
INDUCE-SEQ
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 11, 2024
- Examiner
- STEINPFAD, SARAH E
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INDUCE-SEQ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in agriculture, except fungicides, herbicides, insecticides, and parasiticides | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of cancer, cardiovascular diseases and disorders, neurological diseases and disorders, sleep conditions, diseases and disorders, central nervous system conditions, diseases and disorders, rare diseases and disorders, genetic diseases and disorders, oncological and hematological diseases and disorders, dermatological diseases and disorders, bone diseases and disorders, respiratory diseases and disorders, endocrinological diseases and disorders, circulatory diseases and disorders, gastroenterological diseases and disorders, hormonal diseases and disorders, diabetic diseases and disorders, digestive diseases and disorders, muscular diseases and disorders, immune system diseases and disorders, metabolic diseases and disorders, and ocular diseases and disorders; medical diagnostic reagents and assays for testing of body fluids; chemical reagents for medical purposes; pharmaceutical preparations for use in gene and cell therapies for the treatment of cancer, cardiovascular diseases and disorders, psychiatric diseases and disorders, neurological diseases and disorders, sleep conditions, diseases and disorders, central nervous system conditions, diseases and disorders, rare diseases and disorders, genetic diseases and disorders, oncological and hematological diseases and disorders, dermatological diseases and disorders, bone diseases and disorders, respiratory diseases and disorders, endocrinological diseases and disorders, circulatory diseases and disorders, gastroenterological diseases and disorders, hormonal diseases and disorders, diabetic diseases and disorders, digestive diseases and disorders, muscular diseases and disorders, immune system diseases and disorders, metabolic diseases and disorders, and ocular diseases and disorders; pharmaceutical preparations for use in chemotherapies; diagnostic kits for medical purposes comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer, cardiovascular diseases and disorders, psychiatric diseases and disorders, neurological diseases and disorders, sleep conditions, diseases and disorders, central nervous system conditions, diseases and disorders, rare diseases and disorders, genetic diseases and disorders, oncological and hematological diseases and disorders, dermatological diseases and disorders, bone diseases and disorders, respiratory diseases and disorders, endocrinological diseases and disorders, circulatory diseases and disorders, gastroenterological diseases and disorders, hormonal diseases and disorders, diabetic diseases and disorders, digestive diseases and disorders, muscular diseases and disorders, immune system diseases and disorders, metabolic diseases and disorders, and ocular diseases and disorders; analytical test kits being medical diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer, cardiovascular diseases and disorders, psychiatric diseases and disorders, neurological diseases and disorders, sleep conditions, diseases and disorders, central nervous system conditions, diseases and disorders, rare diseases and disorders, genetic diseases and disorders, oncological and hematological diseases and disorders, dermatological diseases and disorders, bone diseases and disorders, respiratory diseases and disorders, endocrinological diseases and disorders, circulatory diseases and disorders, gastroenterological diseases and disorders, hormonal diseases and disorders, diabetic diseases and disorders, digestive diseases and disorders, muscular diseases and disorders, immune system diseases and disorders, metabolic diseases and disorders, and ocular diseases and disorders | ACTIVE | — |
| 009 | Downloadable computer software for the analysis of genomic data, gene editing data, cell culture data, therapeutic development data, and patient data; downloadable mobile application software for the analysis of genomic data, gene editing data, cell culture data, therapeutic development data, and patient data; apparatus and instruments for scientific or research purposes, namely, laboratory apparatus and instruments for genome sequencing, not for medical purposes | ACTIVE | — |
| 010 | Blood test collection kits comprised of blood collection needles, blood collecting tubes, and blood collection bags for medical purposes; radiation therapy devices | ACTIVE | — |
| 042 | Analytical laboratory services, namely, scientific laboratory services; pharmaceutical research and development services; testing, inspection, research and development of pharmaceutical preparations for gene therapy; testing, inspection, research, and development of pharmaceutical preparations for cell therapies; genome scientific research services; development of new technology for others in the field of medical devices and medical diagnostic apparatuses; medical research services; medical research in the field of infectious disease monitoring and surveillance services; research and development services in the field of antibodies; research, development and consultation related thereto in the field of medical devices and medical diagnostic apparatuses through the use of artificial intelligence; medical research in the field of oncology; toxicity testing and analysis for foodstuffs for scientific research purposes; toxicity testing and analysis for household products for scientific research purposes; computer software development; providing temporary use of online non-downloadable software and software applications using artificial intelligence for medical analysis; software as a service (SaaS) featuring software for the analysis of genomic data, gene editing data, cell culture data, therapeutic development data, and patient data; platform as a service (PaaS) featuring computer software platforms for the analysis of genomic data, gene editing data, cell culture data, therapeutic development data, and patient data; providing temporary use of on-line non-downloadable software and software applications using artificial intelligence for medical analysis; providing temporary use of on-line non-downloadable software and software applications for creating analytic and statistic models for data analysis | ACTIVE | — |
| 044 | Medical profile and medical record analysis designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; medical diagnostic blood testing for identifying and determining the presence and stage of diseases; genome editing therapeutics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BROKEN STRING BIOSCIENCES LIMITED
- Other trademarks owned by BROKEN STRING BIOSCIENCES LIMITED
- Other trademarks owned by BROKEN STRING BIOSCIENCES LIMITED
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named INDUCE-SEQ
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 14, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 21, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 21, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 11, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 11, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 11, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 26, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 26, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 6, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 6, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 21, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 21, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 21, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 21, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 21, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 5, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 5, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 5, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 12, 2023 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Aug 1, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 25, 2023 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jul 19, 2023 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Jul 8, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 8, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 11, 2023 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jun 10, 2023 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 31, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 30, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 26, 2023 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| May 26, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 25, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 24, 2023 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| May 23, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 3, 2023 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Feb 15, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 11, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 9, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |